Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02531425 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC
A Phase 1 study, sponsored by OncoSec Medical Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT02531425: Completed Phase 1 study, sponsored by OncoSec Medical Incorporated.
NCT02531425 is a Phase 1 study that has completed, run by OncoSec Medical Incorporated. The registered enrollment target is 10 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02531425, a Phase 1 study, has completed, sponsored by OncoSec Medical Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Intratumoral plasmid IL-12 electroporation (IT-pIL12-EP) will be administered to approximately 10 patients with triple negative breast cancer (TNBC) with cutaneous or subcutaneous disease. Patients will receive one complete cycle of therapy, consisting of local injection of plasmid IL-12 (pIL-12) followed immediately by electroporation (EP), into accessible tumor lesions. IT-pIL12-EP will be administered in Days 1, 5, and 8 of the single 28-day cycle.
Primary Outcome
Paired tumor biopsy samples will be quantitatively analyzed for the number and distribution of tumor infiltrating lymphocytes (TILs).
Interventions
- BIOLOGICAL IT-pIL12-EP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-09 |
| Est. Completion | 2018-07 |
| Phase | Phase 1 |
What the finished NCT02531425 record still lists
NCT02531425 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 1 intervention - of which IT-pIL12-EP is the first listed.
NCT02531425 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02531425 about?
NCT02531425 is a clinical study titled "Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC". Intratumoral plasmid IL-12 electroporation (IT-pIL12-EP) will be administered to approximately 10 patients with triple negative breast cancer (TNBC) with cutaneous or subcutaneous disease. Patients will receive one complete cycle of therapy, consisting of local injection of plasmid IL-12 (pIL-12) fo...
What is the current status of trial NCT02531425?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2015-09. Estimated completion is 2018-07.
What interventions are being tested in trial NCT02531425?
The interventions under investigation include: IT-pIL12-EP (BIOLOGICAL).
Who is sponsoring clinical trial NCT02531425?
This trial is sponsored by OncoSec Medical Incorporated, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02531425's enrollment target sits among peer trials
10 1913th of 2000 higher than 46 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia